Trial Profile
Phase II study: Systemic treatment with alternating weekly regimen of temozolomide and monthly fotemustine combination in recurrent glioblastoma patients.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Jul 2011
Price :
$35
*
At a glance
- Drugs Fotemustine (Primary) ; Temozolomide (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 29 Jul 2011 New trial record